Rosiglitazone
- Generic Name
- Rosiglitazone
- Brand Names
- Avandamet, Avandia
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19N3O3S
- CAS Number
- 122320-73-4
- Unique Ingredient Identifier
- 05V02F2KDG
- Background
Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellula...
- Indication
Rosiglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Insulin Resistance and Intramyocellular Lipid Content in Glucose Intolerant Subjects Receiving Rosiglitazone
- First Posted Date
- 2008-09-03
- Last Posted Date
- 2008-09-03
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT00746174
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States
Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2008-08-20
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Emory University
- Target Recruit Count
- 36
- Registration Number
- NCT00738023
- Locations
- 🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States
Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance
- First Posted Date
- 2008-08-12
- Last Posted Date
- 2008-08-12
- Lead Sponsor
- Denver Research Institute
- Target Recruit Count
- 60
- Registration Number
- NCT00733174
- Locations
- 🇺🇸
South Federal Family Practice, Denver, Colorado, United States
Rosiglitazone Versus Rosiglitazone and Metformin Versus Rosiglitazone and Avandia in the Treatment of Nonalcoholic Steatohepatitis (NASH)
- Conditions
- Interventions
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2009-06-19
- Lead Sponsor
- Brooke Army Medical Center
- Target Recruit Count
- 165
- Registration Number
- NCT00699036
- Locations
- 🇺🇸
Brooke Army Medical Center, San Antonio, Texas, United States
Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients
- Conditions
- Interventions
- First Posted Date
- 2008-05-20
- Last Posted Date
- 2013-10-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 597
- Registration Number
- NCT00680745
- Locations
- 🇺🇦
Research Site, Zaporozhye, Ukraine
Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health
- First Posted Date
- 2008-05-19
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 226
- Registration Number
- NCT00679939
- Locations
- 🇪🇸
GSK Investigational Site, Petrer, Spain
Physical Exercise Versus Rosiglitazone in CAD and Prediabetes
- Conditions
- Interventions
- First Posted Date
- 2008-05-12
- Last Posted Date
- 2010-02-02
- Lead Sponsor
- University of Leipzig
- Target Recruit Count
- 45
- Registration Number
- NCT00675740
Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study
- Conditions
- Interventions
- First Posted Date
- 2008-03-21
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- Silva Arslanian
- Target Recruit Count
- 65
- Registration Number
- NCT00640224
- Locations
- 🇺🇸
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
Diagnosis and Therapy of Vulnerable Atherosclerotic Plaque
- Conditions
- Interventions
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2012-11-02
- Lead Sponsor
- Aristotle University Of Thessaloniki
- Target Recruit Count
- 300
- Registration Number
- NCT00636766
- Locations
- 🇬🇷
General Hospital of Thessaloniki "Hippokratio", Thessaloniki, Greece
Effect of GSK376501 on CYP450 Activity in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 23
- Registration Number
- NCT00615212
- Locations
- 🇺🇸
GSK Investigational Site, Buffalo, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.